Login to Your Account

MacroGenics Boosts Anticancer Pipeline with Raven Acquisition

By Trista Morrison

Thursday, July 17, 2008
In a deal to be announced Thursday morning, MacroGenics Inc. is bolstering its anticancer antibody pipeline with the acquisition of Raven Biotechnologies Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription